Stabilized single domain antibodies

a single-domain, antibody technology, applied in the direction of antibody medical ingredients, antibody mimetics/scaffolds, fusion polypeptides, etc., can solve the problems of high cost of antibody production in mammalian cells, large protein doses, and discouraged development of traditional antibody therapeutics for these applications

Inactive Publication Date: 2007-08-02
ABLYNX NV
View PDF58 Cites 205 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0068] One embodiment of the present invention is a use of a polypeptide construct as described above, or a nucleic acid as described above for the preparation of a medicament for treating, preventing and/or alleviating the symptoms of a disease requiring a therapeutic or diagnostic compound which is not rapidly cleared from the circulation.
[0069] One embodiment of the present invention is a polypeptide construct as described above, or a nucleic acid as described above for use in treating, preventing and/or all

Problems solved by technology

This will require large doses of protein over a long period of time.
Since the cost of antibody production in mammalian cells is high, the development of traditional antibody therapeutics for these applications has been discouraged.
Such chemical methods, however, suffer from a number of disadvantages, such as inactivation of the target protein or peptide due to the chemical modification of certain amino acid side chains, instability of the target protein/peptide during the chemical reaction.
The drawback of these peptide-based approaches is that the peptides have to fold properly and be accessible to binding to serum albumin when fused to the therapeutic protein.
Therefore, these peptides are inherently unstable and have affinities in the submicromolar range rather than subnanomolar or low nanomolar range, as is the case with conventional antibodies.
However, such heterospecific constructs based on conventional antibodies or Fab fragments have several important drawbacks: these are complex, large molecules composed of two polypeptide chains (VH and VL) a

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Stabilized single domain antibodies
  • Stabilized single domain antibodies
  • Stabilized single domain antibodies

Examples

Experimental program
Comparison scheme
Effect test

example 1

Immunization of Llamas

[0308] One llama was Immunized with human serum albumin (HSA). The immunization scheme is summarized in Table 1.

example 2

Repertoire Cloning

[0309] Peripheral blood lymphocytes (PBLs) were isolated by centrifugation on a density gradient (Ficoll-Paque Plus Amersham Biosciences). PBLs were used to exitact total RNA (Chomczynski and Sacchi 1987). cDNA was prepared on 100 μg total RNA with MMLV Reverse Transcriptase (Gibco BRL) using oligo d(T) oligonucleotides. The cDNA was purified with a phenol / chloroform extraction, followed by an ethanol precipitation and subsequently used as template to amplify the VHH repertoire.

[0310] In a first PCR, the repertoire of both conventional (1.6 kb) and heavy-chain (1.3 kb) antibody gene segments were amplified using a leader specific primer (5′-GGCTGAGCTCGGTGGTCCTGGCT-3′) (SEQ ID No 41) and the oligo d(T) primer (5′-AACTGGAAGAATTCGCGGCCGCAGGAATTTTTTTTTTTTTTTTTT-3′) (SEQ ID No 42). The resulting DNA fragments were separated by agarose gel electrophoresis and the 1.3 kb fragment, encoding heavy-chain antibody segments was purified from the agarose gel. A second PCR was...

example 3

Rescue of the Library, Phage Preparation

[0311] The library was grown at 37° C. in 10 ml 2×TY medium containing 2% glucose, and 100 μg / ml ampicillin, until the OD600 nm reached 0.5. M13KO7 phages (1012) were added and the mixture was incubated at 37° C. for 2×30 minutes, first without shaking, then with shaking at 100 rpm. Cells were centrifuged for 10 minutes at 4500 rpm at room temperature. The bacterial pellet was resuspended in 50 ml of 2×TY medium containing 100 μg / ml ampicillin and 25 μg / ml kanamycin, and incubated overnight at 37° C. with vigorously shaking at 250 rpm. The overnight cultures were centrifuged for 15 minutes at 10,000 rpm at 4° C. Phages were PEG precipitated (20% poly-ethylene-glycol and 1.5 M NaCl) and centrifuged for 30 minutes at 10,000 rpm. The pellet was resuspended in 20 ml PBS. Phages were again PEG precipitated and centrifuged for 30 minutes at 20,000 rpm and 4° C. The pellet was dissolved in 5 ml PBS-1% casein. Phages were titrated by infection of TG1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Molar densityaaaaaaaaaa
Molar densityaaaaaaaaaa
Molar densityaaaaaaaaaa
Login to view more

Abstract

The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems.

Description

FIELD OF THE INVENTION [0001] The present invention provides heterospecific polypeptide constructs comprising one or more single domain antibodies, said constructs having improved stability in vivo and their use in diagnosis and therapy. BACKGROUND OF THE INVENTION [0002] Polypeptide therapeutics and in particular antibody-based therapeutics have significant potential as drugs because they have exquisite specificity to their target and a low inherent toxicity. However, in order to be effective as therapeutic agent, their pharmacokinetic profile should be optimized. The majority of current antibody applications are for acute disorders. There are however significant opportunities to develop antibody therapeutics for chronic conditions. This will require large doses of protein over a long period of time. Since the cost of antibody production in mammalian cells is high, the development of traditional antibody therapeutics for these applications has been discouraged. An alternative appro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K48/00A61K39/395C07K16/42C07H21/04C12P21/06A61P11/06A61P19/02A61P31/06A61P31/16A61P35/00A61P37/06C07K16/10C07K16/12C07K16/18C07K16/24C07K16/28C07K16/30C07K16/36C07K16/40C07K16/46C12N15/13G01N33/577
CPCA61K2039/505C07K2317/34C07K16/241C07K16/249C07K16/2863C07K16/2875C07K16/36C07K16/40C07K16/4291C07K2317/22C07K2317/24C07K2317/31C07K2317/565C07K2317/569C07K2317/626C07K2319/00C07K16/18A61P1/00A61P11/06A61P13/12A61P15/08A61P17/00A61P17/06A61P19/02A61P21/04A61P25/02A61P25/28A61P29/00A61P31/06A61P31/16A61P35/00A61P37/02A61P37/06A61P7/06A61P9/14A61P3/10
Inventor SILENCE, KARENLAUWEREYS, MARCDREIER, TORSTEN
Owner ABLYNX NV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap